ID   P-STS
AC   CVCL_L298
SY   PSTS
DR   cancercelllines; CVCL_L298
DR   GEO; GSM966945
DR   PharmacoDB; PSTS_1278_2019
DR   Progenetix; CVCL_L298
DR   Wikidata; Q54937197
RX   PubMed=19528452;
RX   PubMed=22538498;
RX   PubMed=28465562;
RX   PubMed=29444910;
CC   Doubling time: ~4 days (PubMed=19528452); ~1 week (PubMed=28465562).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273Cys (c.817C>T); ClinVar=VCV000043594; Zygosity=Homozygous (PubMed=29444910).
CC   Omics: Array-based CGH.
CC   Omics: SNP array analysis.
CC   Derived from site: In situ; Small intestine, ileum; UBERON=UBERON_0002116.
ST   Source(s): PubMed=29444910
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11
ST   D13S317: 8,13
ST   D16S539: 12,13
ST   D21S11: 29,31
ST   D5S818: 12
ST   D7S820: 10,13
ST   TH01: 9,9.3
ST   TPOX: 8
ST   vWA: 20,21,22
DI   NCIt; C6422; Midgut neuroendocrine tumor G1
DI   ORDO; Orphanet_100093; Carcinoid syndrome
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_L296 ! H-STS
OI   CVCL_L297 ! L-STS
SX   Male
AG   42Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 05-10-23; Version: 17
//
RX   PubMed=19528452;
RA   Pfragner R., Behmel A., Hoger H., Beham A., Ingolic E., Stelzer I.,
RA   Svejda B., Moser V.A., Obenauf A.C., Siegl V., Haas O., Niederle B.;
RT   "Establishment and characterization of three novel cell lines -- P-STS,
RT   L-STS, H-STS -- derived from a human metastatic midgut carcinoid.";
RL   Anticancer Res. 29:1951-1961(2009).
//
RX   PubMed=22538498; DOI=10.1159/000338793;
RA   Grozinsky-Glasberg S., Shimon I., Rubinfeld H.;
RT   "The role of cell lines in the study of neuroendocrine tumors.";
RL   Neuroendocrinology 96:173-187(2012).
//
RX   PubMed=28465562; DOI=10.1038/s41598-017-01453-5;
RA   Pfanzagl B., Mechtcheriakova D., Meshcheryakova A., Aberle S.W.,
RA   Pfragner R., Jensen-Jarolim E.;
RT   "Activation of the ileal neuroendocrine tumor cell line P-STS by
RT   acetylcholine is amplified by histamine: role of H3R and H4R.";
RL   Sci. Rep. 7:1313-1313(2017).
//
RX   PubMed=29444910; DOI=10.1530/ERC-17-0445;
RA   Hofving T., Arvidsson Y., Almobarak B., Inge L., Pfragner R.,
RA   Persson M., Stenman G., Kristiansson E., Johanson V., Nilsson O.;
RT   "The neuroendocrine phenotype, genomic profile and therapeutic
RT   sensitivity of GEPNET cell lines.";
RL   Endocr. Relat. Cancer 25:367-380(2018).
//